Form 8-K Arcus Biosciences, Inc. For: Apr 16
Tweet
Share
E-mail
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
|
|
(State or other jurisdiction of incorporation or organization) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
(Address of principal executive offices)
Registrant’s telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Titles of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on which Registered |
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company:
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 3.01 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On April 16, 2021, Arcus Biosciences, Inc. notified the New York Stock Exchange that the Arcus Board of Directors determined that David Lacey, an independent director of Arcus and a member of the Audit Committee of the Board of Directors of Arcus, did not meet the heightened independence requirements for service on the Audit Committee as required by Securities and Exchange Commission Rule 10A-3 and NYSE Rule 303A.06 due to his compensation for serving on Arcus’s scientific advisory board. Upon making this determination, the Arcus Board of Directors appointed Andrew Perlman to the Audit Committee in place of Dr. Lacey and appointed Dr. Lacey to the Nominating and Corporate Governance Committee in place of Dr. Perlman.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ARCUS BIOSCIENCES, INC. |
||
|
|
|
|
|
|
|
Date: April 16, 2021 |
|
By: |
|
/s/ Terry Rosen, Ph.D. |
|
|
|
|
|
Terry Rosen, Ph.D. |
|
|
|
|
|
Chief Executive Officer |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
- Aurora Humanitarian Initiative and UCLA's The Promise Institute for Human Rights unveil speakers for May forum and prize events
- Digital Health Expert Julianne Bride to Lead Strategic Partnerships & Client Success at CareHive Health
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
